Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Tumour burden and efficacy of immune-checkpoint inhibitors
FG Dall'Olio, A Marabelle, C Caramella… - Nature reviews Clinical …, 2022 - nature.com
Accumulating evidence suggests that a high tumour burden has a negative effect on
anticancer immunity. The concept of tumour burden, simply defined as the total amount of …
anticancer immunity. The concept of tumour burden, simply defined as the total amount of …
Clinical review on the management of metastatic renal cell carcinoma
J Tran, MC Ornstein - JCO Oncology Practice, 2022 - ascopubs.org
Renal cell carcinomas vary considerably in their tumor biology and disease course, which is
reflected in the range of treatment paradigms in localized and metastatic renal cell …
reflected in the range of treatment paradigms in localized and metastatic renal cell …
Management of metastatic clear cell renal cell carcinoma: ASCO guideline
PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …
[HTML][HTML] Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Escudier, C Porta, M Schmidinger… - Annals of …, 2019 - Elsevier
Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women,
respectively, thus representing the 7th most common cancer in men, and the 10th most …
respectively, thus representing the 7th most common cancer in men, and the 10th most …
Clear cell renal cell carcinoma: from biology to treatment
Simple Summary Over the past two decades, biological discoveries have transformed the
treatment strategies for renal cell carcinoma. These advances have led to the development …
treatment strategies for renal cell carcinoma. These advances have led to the development …
Clinical cancer advances 2020: annual report on progress against cancer from the American Society of Clinical Oncology
Each year Clinical Cancer Advances: ASCO's Annual Report on Progress Against Cancer
highlights the most important clinical research advances of the past year, including the …
highlights the most important clinical research advances of the past year, including the …
Risks from deferring treatment for genitourinary cancers: a collaborative review to aid triage and management during the COVID-19 pandemic
Context The coronavirus disease 2019 (COVID-19) pandemic is leading to delays in the
treatment of many urologic cancers. Objective To provide a contemporary picture of the risks …
treatment of many urologic cancers. Objective To provide a contemporary picture of the risks …
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)
Background Surgery for renal cell carcinoma (RCC) with venous tumour thrombus (VTT)
extension into the renal vein (RV) and/or inferior vena cava (IVC) has high peri-surgical …
extension into the renal vein (RV) and/or inferior vena cava (IVC) has high peri-surgical …
Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy?
A Méjean, A Ravaud, S Thezenas, C Chevreau… - European Urology, 2021 - Elsevier
Background The CARMENA trial in patients with metastatic renal cell carcinoma (mRCC)
demonstrated that treatment with sunitinib alone was noninferior to cytoreductive …
demonstrated that treatment with sunitinib alone was noninferior to cytoreductive …
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma
Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery
for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease …
for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease …